Business Context and Reporting Period
This Form 8-K Current Report was filed by Akebia Therapeutics, Inc. on May 12, 2022. The filing addresses two material events: the termination of collaboration agreements with Otsuka Pharmaceutical Co. Ltd. regarding the lead investigational product candidate vadadustat, and a deficiency notice from Nasdaq regarding the company's stock bid price.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, or debt figures. However, it notes that under the terminated agreements, Otsuka currently funds 80% of the global development costs for vadadustat. The loss of this funding arrangement represents a significant change to the company's cost structure and liquidity outlook, though specific dollar amounts are not provided in this text.
Material Changes Versus Prior Period
- Termination of Otsuka International Agreement: Otsuka exercised its right to terminate the agreement for convenience, effective May 13, 2023. This agreement covered the development and commercialization of vadadustat in Europe, Russia, China, Canada, Australia, and the Middle East.
- Termination of Otsuka U.S. Agreement: Otsuka notified the company of termination for convenience, effective May 13, 2023. Additionally, Otsuka alleged material breaches by Akebia that could trigger an earlier termination as soon as June 12, 2022. Akebia disputes these allegations and intends to contest the early termination.
- Regaining Rights: Upon termination, Akebia will regain exclusive rights to develop and commercialize vadadustat worldwide, excluding Japan and certain Asian countries covered by a separate agreement with Mitsubishi Tanabe Pharma Corporation.
- Nasdaq Listing Deficiency: The company received a deficiency letter stating its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary: Akebia intends to continue supporting the regulatory approval process for vadadustat in jurisdictions where Otsuka had submitted applications (EMA, UK, Switzerland, Australia). The company plans to monitor its stock price and may consider a reverse stock split to regain compliance with Nasdaq listing rules.
Risks and Contingencies:
- Funding Risk: The termination of agreements ends Otsuka's funding of 80% of vadadustat's global development costs, creating a potential liquidity strain.
- Legal Dispute: Akebia faces a potential early termination of the U.S. agreement by June 12, 2022, based on alleged material breaches which the company disputes.
- Delisting Risk: The company has 180 days (until November 8, 2022) to regain compliance with the $1.00 bid price requirement. Failure to do so may result in delisting from the Nasdaq Global Market, though a transfer to the Nasdaq Capital Market may be possible.
Important Facts for Investor Verification
- Verify the specific financial impact of losing Otsuka's 80% funding contribution for vadadustat development.
- Monitor the status of the dispute regarding alleged material breaches and the potential for U.S. agreement termination by June 12, 2022.
- Track the company's stock price to determine if it meets the $1.00 bid price requirement within the 180-day compliance period.
- Confirm the timeline for Akebia's assumption of full commercialization responsibilities for vadadustat outside of Japan and certain Asian territories.